BioSyent

BioSyent EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of BioSyent (RX.V) as of Oct 6, 2026 is 20.38. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 44.25 — a change of -53.94% (lower).

EV/FCF

20.38

YoY

-53.94%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of BioSyent is 2026 20.38 . EV/FCF (Enterprise Value to Free Cash Flow) of BioSyent was 2025 44.25 . It decreases by -53.94% lower compared to the previous year.

The BioSyent EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
26.16 CAD
Jan 1, 2019
38.54 CAD
Jan 1, 2020
22.59 CAD
Jan 1, 2021
32.53 CAD
Jan 1, 2022
33.50 CAD
Jan 1, 2023
47.83 CAD
Jan 1, 2024
44.25 CAD
Jan 1, 2025
20.38 CAD
The BioSyent EV/FCF history
YEAREV/FCFYoY
20.38-53.94%
44.25-7.48%
47.83+42.76%
33.50+2.99%
32.53+43.98%
22.59-41.38%
38.54+47.32%
26.16-1.19%
26.47-34.72%
40.55-59.36%
99.78+112.10%
47.04—
Access this data via the Eulerpool API

BioSyent Stock analysis

What does BioSyent do? Biosyent Inc is a Canadian pharmaceutical company founded in 2004. The company's headquarters are located in Mississauga, Ontario. Biosyent is listed on the Toronto Stock Exchange and has a market capitalization of approximately 140 million Canadian dollars. The company's business model is based on acquiring domestic pharmaceutical and nutraceutical products and marketing them in Canada. Biosyent operates in two main divisions: Pharma and Nutraceuticals. The Pharma division includes products such as RepaGyn, a vaginal gel for treating dryness and irritation during menopause, as well as the antiemetic Setofilm/Tablets for the prevention and treatment of nausea and vomiting. The Nutraceutical division includes products such as FeraMAX, a supplement that increases iron in the diet and helps prevent the development of anemia. Biosyent also offers vitamin-rich dietary supplements such as Aerobic Oxygen and Calm Biotic, targeting health-conscious customers. Another important area of Biosyent is Hospital Specialty Pharmaceuticals, targeting hospitals and healthcare facilities. This includes products like Cysview and Cysview Kit, used to detect non-muscle invasive bladder cancer and improve fluorescence during cystoscopy. Biosyent also offers infusion sets designed for intravenous medication administration. Overall, Biosyent has more than 20 products in various categories including women's and men's health, ophthalmology, immunology, and oncology. Over the years, Biosyent Inc has received various awards for its products and business practices. In 2012, the company received the Bio-Wellness Award for its flagship product, RepaGyn. While Biosyent has ambitions to expand its presence in international markets, the company remains primarily focused on the Canadian market. Biosyent relies mainly on a low-cost marketing strategy that aims to directly target patients in order to market its products in a simple way. Overall, Biosyent has a strong market position in Canada and a portfolio of well-established products. The company has a successful history and appears ready for the future with a strong pipeline and a growing presence in the Canadian market. BioSyent is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioSyent stock

EV/FCF (Enterprise Value to Free Cash Flow) of BioSyent is 20.38 in 2026.

EV/FCF (Enterprise Value to Free Cash Flow) of BioSyent changed from 44.25 to 20.38, representing a -53.94% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) BioSyent since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s BioSyent with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — BioSyent

All Key Metrics — BioSyent